Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Pulmonary Pharmacology and Therapeutics

Volumn 40, Issue , 2016, Pages 95-103

  Rogliani, Paola ^a   Calzetta, Luigino ^a   Cavalli, Francesco ^a   Matera, Maria Gabriella ^b   Cazzola, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

IPF; Meta analysis; Therapy

Indexed keywords

ACETYLCYSTEINE; NINTEDANIB; PIRFENIDONE; PLACEBO; ANTIINFLAMMATORY AGENT; ENZYME INHIBITOR; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANOREXIA; ARTICLE; CLINICAL ASSESSMENT; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEADACHE; HUMAN; INSOMNIA; LOSS OF APPETITE; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ACETYLCYSTEINE; ANTI-INFLAMMATORY AGENTS; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PRACTICE GUIDELINES AS TOPIC; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84982279600     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2016.07.009     Document Type: Article

References (66)

1. [1] Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183 (2011), 788–824.
2. [2] Raghu, G., Weycker, D., Edelsberg, J., Bradford, W.Z., Oster, G., Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174 (2006), 810–816.
3. [3] Raghu, G., Chen, S.Y., Yeh, W.S., Maroni, B., Li, Q., Lee, Y.C., et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir. Med. 2 (2014), 566–572.
4. [4] Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C.A., Azuma, A., Behr, J., et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 192 (2015), e3–19.
5. [5] Loveman, E., Copley, V.R., Scott, D.A., Colquitt, J.L., Clegg, A.J., O'Reilly, K.M., Comparing new treatments for idiopathic pulmonary fibrosis–a network meta-analysis. BMC Pulm. Med., 15, 2015, 37.
6. [6] Aravena, C., Labarca, G., Venegas, C., Arenas, A., Rada, G., Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One, 10, 2015, e0136160.
7. [7] Atkins, C.P., Loke, Y.K., Wilson, A.M., Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir. Med. 108 (2014), 376–387.
8. [8] Richeldi, L., Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respir. Res., 14(Suppl. 1), 2013, S4.
9. [9] Richeldi, L., Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 21 (2012), 147–151.
10. [10] Spagnolo, P., Del Giovane, C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E.H., et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev., 8, 2010 CD003134.
11. [11] Canestaro, W., Forrester, S., Raghu, G., Ho, L., Devine, B., Drug therapy for treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 149 (2016), 756–766.
12. [12] Sakamoto, S., Muramatsu, Y., Satoh, K., Ishida, F., Kikuchi, N., Sano, G., et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology 20 (2015), 445–452.
13. [13] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 6, 2009, e1000097.
14. [14] Shariff, S.Z., Bejaimal, S.A., Sontrop, J.M., Iansavichus, A.V., Haynes, R.B., Weir, M.A., et al. Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches. J. Med. Internet Res., 15, 2013, e164.
15. [15] American Thoracic, S., European Respiratory, S., American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the american thoracic society (ATS), and the european respiratory society (ERS) was adopted by the ATS board of directors, june 2001 and by the ERS executive committee, june 2001. Am. J. Respir. Crit. Care Med. 165 (2002), 277–304.
16. [16] Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin. Trials 17 (1996), 1–12.
17. [17] Sterne, J.A., Gavaghan, D., Egger, M., Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 53 (2000), 1119–1129.
18. [18] Sterne, J.A., Egger, M., Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 54 (2001), 1046–1055.
19. [19] Egger, M., Smith, G.D., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
20. [20] Borenstein, M., Introduction to Meta-analysis. 2009, John Wiley & Sons, Chichester, U.K.
21. [21] DeCoster J. Meta-analysis notes. Retrieved April. 2004;1:2007.
22. [22] Turner, J.R., Durham, T.A., Meta-methodology: conducting and reporting meta-analyses. J. Clin. Hypertens. (Greenwich) 16 (2014), 91–93.
23. [23] Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A.G., Rogliani, P., et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 24 (2015), 451–461.
24. [24] Wallace, B.C., Dahabreh, I.J., Trikalinos, T.A., Lau, J., Trow, P., Schmid, C.H., Closing the gap between methodologists and end-users: r as a computational back-end. J. Stat. Softw. 49 (2012), 1–15.
25. [25] Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36 (2012), 1–48.
26. [26] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
27. [27] Thorlund, K., Imberger, G., Walsh, M., Chu, R., Gluud, C., Wetterslev, J., et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis–a simulation study. PLoS One, 6, 2011, e25491.
28. [28] Homma, S., Azuma, A., Taniguchi, H., Ogura, T., Mochiduki, Y., Sugiyama, Y., et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 17 (2012), 467–477.
29. [29] Salanti, G., Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Synth. Methods 3 (2012), 80–97.
30. [30] Peat, J., Mellis, C., Williams, K., Health Science Research: a Handbook of Quantitative Methods. 2002, Sage.
31. [31] Noble, P.W., Albera, C., Bradford, W.Z., Costabel, U., du Bois, R.M., Fagan, E.A., et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur. Respir. J. 47 (2016), 243–253.
32. [32] Kirsten, A.M., Richeldi, L., Roman, J., Le Maulf, F., Hallmann, C., Stowasser, S., et al. Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF). Abstract Presented at ICLAF 2014. Pneumologie, 2015, 69.
33. [33] Aravena, C., Labarca, G., Venegas, C., Arenas, A., Rada, G., Correction: pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One, 10, 2015, e0140288.
34. [34] Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171 (2005), 1040–1047.
35. [35] Raghu, G., Anstrom, K.J., King, T.E. Jr., Lasky, J.A., Martinez, F.J., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 366 (2012), 1968–1977.
36. [36] Martinez, F.J., de Andrade, J.A., Anstrom, K.J., King, T.E. Jr., Raghu, G., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2093–2101.
37. [37] Noble, P.W., Albera, C., Bradford, W.Z., Costabel, U., Glassberg, M.K., Kardatzke, D., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
38. [38] Calzetta, L., Matera, M.G., Cazzola, M., Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur. J. Pharmacol. 761 (2015), 168–173.
39. [39] Calzetta, L., Rogliani, P., Ora, J., Puxeddu, E., Cazzola, M., Matera, M.G., LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur. Respir. Rev., 2016.
40. [40] Richeldi, L., Costabel, U., Selman, M., Kim, D.S., Hansell, D.M., Nicholson, A.G., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365 (2011), 1079–1087.
41. [41] Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2071–2082.
42. [42] Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35 (2010), 821–829.
43. [43] Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H.M., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353 (2005), 2229–2242.
44. [44] King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., Fagan, E.A., Glaspole, I., Glassberg, M.K., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2083–2092.
45. [45] Sakamoto, S., Itoh, T., Muramatsu, Y., Satoh, K., Ishida, F., Sugino, K., et al. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Intern Med. 52 (2013), 2495–2501.
46. [46] Harari, S., Caminati, A., Albera, C., Vancheri, C., Poletti, V., Pesci, A., et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir. Med. 109 (2015), 904–913.
47. [47] Behr, J., Bendstrup, E., Crestani, B., Gunther, A., Olschewski, H., Skold, C.M., et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Resp. Med. 4 (2016), 445–453.
48. [48] Cazzola, M., Calzetta, L., Rogliani, P., Puxeddu, E., Facciolo, F., Matera, M.G., Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm. Pharmacol. Ther. 36 (2016), 1–9.
49. [49] Calzetta, L., Soggiu, A., Roncada, P., Bonizzi, L., Pistocchini, E., Urbani, A., et al. Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. Eur. J. Pharmacol. 765 (2015), 463–471.
50. [50] Cazzola, M., Calzetta, L., Ora, J., Puxeddu, E., Rogliani, P., Matera, M.G., Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir. Med. 109 (2015), 1305–1311.
51. [51] Calzetta, L., Cazzola, M., Page, C.P., Rogliani, P., Facciolo, F., Matera, M.G., Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm. Pharmacol. Ther. 32 (2015), 15–23.
52. [52] Cazzola, M., Calzetta, L., Page, C.P., Rogliani, P., Facciolo, F., Gavalda, A., et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur. J. Pharmacol. 745 (2014), 135–143.
53. [53] Cazzola, M., Calzetta, L., Segreti, A., Facciolo, F., Rogliani, P., Matera, M.G., Translational study searching for synergy between glycopyrronium and indacaterol. COPD 12 (2015), 175–181.
54. [54] Calzetta, L., Page, C.P., Spina, D., Cazzola, M., Rogliani, P., Facciolo, F., et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther. 346 (2013), 414–423.
55. [55] Rogliani, P., Calzetta, L., Rendina, E.A., Massullo, D., Dauri, M., Rinaldi, B., et al. The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm. Pharmacol. Ther. 26 (2013), 325–331.
56. [56] Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 45 (2015), 1382–1392.
57. [57] European Medicines Agency. EMA/CHMP/115147/2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002154/WC500103073.pdf. 2010.
58. [58] Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011 Available from: www.cochrane-handbook.org The Cochrane Collaboration.
59. [59] Sutton, A.J., Cooper, N.J., Lambert, P.C., Jones, D.R., Abrams, K.R., Sweeting, M.J., Meta-analysis of rare and adverse event data. Expert Rev. Pharmacoecon Outcomes Res. 2 (2002), 367–379.
60. [60] Schechtman, E., Odds ratio, relative risk, absolute risk reduction, and the number needed to treat–which of these should we use?. Value Health 5 (2002), 431–436.
61. [61] Raghu, G., Collard, H.R., Anstrom, K.J., Flaherty, K.R., Fleming, T.R., King, T.E. Jr., et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am. J. Respir. Crit. Care Med. 185 (2012), 1044–1048.
62. [62] Antoniou, K.M., Margaritopoulos, G.A., Siafakas, N.M., Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur. Respir. Rev. 22 (2013), 281–291.
63. [63] Rogliani, P., Mura, M., Mattia, P., Ferlosio, A., Farinelli, G., Mariotta, S., et al. HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. Respir. Med. 102 (2008), 1753–1761.
64. [64] Wuyts, W.A., Antoniou, K.M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis?. lancet Respir. Med. 2 (2014), 933–942.
65. [65] Vancheri, C., du Bois, R.M., A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur. Respir. J. 41 (2013), 262–269.
66. [66] Rogliani, P., Mura, M., Assunta Porretta, M., Saltini, C., New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 2 (2008), 75–93.